

The Commonwealth of Massachusetts

Executive Office of Health and Human Services
Department of Public Health
Bureau of Health Care Safety and Quality
Medical Use of Marijuana Program
99 Chauncy Street, 11th Floor, Boston, MA 02111

MARYLOU SUDDERS Secretary

MONICA BHAREL, MD, MPH Commissioner

Tel: 617-660-5370 www.mass.gov/medicalmarijuana

Governor KARYN F POLITO

KARYN E. POLITO Lieutenant Governor

(Proposed - Not Final)

Title: Protocol for Sampling and Analysis of Finished Medical Marijuana Products and Marijuana-Infused Products for Massachusetts Registered Medical Marijuana Dispensaries

Exhibit 6. Analysis Requirements for Microbiological Contaminants and Mycotoxins in Medical Marijuana Products^a

Cannabis Material	Total Viable Aerobic Bacteria (CFU/g)	Total Yeast and Mold (CFU/g)	Total Coliforms (CFU/g)	Bile- tolerant Gram- negative Bacteria (CFU/g)	E Coli (pathogenic strains) and Salmonella spp.	Mycotoxins ^c
Unprocessed Materials ^b	10 ⁵	10 ⁴	10 ³	10 ³		
Processed Materials ^b	10 ⁵	10 ⁴	10 ³) 10 ³	Not detected in 1 g	<20 µg of any mycotoxin per kg of material
CO ₂ and Solvent-based Extracts	10 ⁴	10 ³	10 ²	10 ²		

CFU: colony forming unit

^a Except for mycotoxins, analysis requirements are based on AHP (2013).

^b Unprocessed materials include minimally processed crude cannabis preparations such as inflorescences, accumulated resin glands (kief), and compressed resin glands (hashish). Processed materials include various solid or liquid infused edible preparations, oils, topical preparations, and water-processed resin glands ("bubble hash") (AHP, 2013).

^c Mycotoxins include alfatoxin B1, alfatoxin B2, alfatoxin G1, alfatoxin G2, and Ochratoxin A.